Armacokinetic profile. Translation in two advanced BC patients, resulted in no unwanted effects, confirming prior observations on the Bisantrene MedChemExpress biosafety of radiotracers depending on the potent GRPR-antagonist [DPhe6 ,LeuNHEt13 ]BBN(6-13) and on GRPR-antagonist radioligands in general. In addition, it revealed the capacity of [99m Tc]Tc-DB15 to detect many metastatic BC lesions, each in the skeleton and in soft tissues, but these findings need to be confirmed prospectively inside a devoted human study. In view with the above, further clinical evaluation appears to be warranted to establish the diagnostic worth of [99m Tc]Tc-DB15 in BC, Pc, as well as other GRPR-expressing human malignancies.Supplementary Components: The following are available on the net at https://www.mdpi.com/article/ 10.3390/cancers13205093/s1, Figure S1: Typical radiochromatogram of HPLC analysis of [99m Tc]TcDB15 (preclinical); Figure S2: Typical radiochromatogram of HPLC analysis of [99m Tc]Tc-DB15 (for patients); Figure S3: Complete body scan three h pi of [99m Tc]Tc-DB15 in patient 1 (with anterior and posterior projection); Figure S4: PET/CT 1 h pi of [18 F]FDG in patient 1; Table S1: Numerical biodistribution data for [99m Tc]Tc-DB15 in PC-3 xenograft-bearing SCID mice at 1, four and 24 h pi; Table S2: Numerical biodistribution data for [99m Tc]Tc-DB15 in T-47D xenograft-bearing SCID mice at 1, 4 and 24 h pi.Cancers 2021, 13,12 ofAuthor Contributions: Conceptualization, B.A.N., R.M. and T.M.; methodology, B.A.N., A.K., P.K., B.J., B.B., D.I. and T.M.; validation, B.A.N., R.M., R.C., D.I. and T.M.; investigation, B.A.N., A.K., P.K., B.J., B.B., R.C., D.I. and T.M.; resources, R.M., R.C. and T.M.; data curation, P.K., R.M., R.C. and T.M.; writing–original draft preparation, T.M.; writing–review and editing, all co-authors; supervision, B.A.N., R.M., R.C. and T.M.; c-di-AMP supplier project administration, R.M., R.C. and T.M.; funding acquisition, R.M., R.C. and T.M. All authors have study and agreed to the published version with the manuscript. Funding: The preclinical study was co-financed by Greece as well as the European Union (European Regional Development Fund) via the project “NCSRD–INRASTES analysis activities within the framework from the national RIS3” (MIS 5002559), implemented below the “Action for the Strategic Improvement on the Study and Technological Sector”, funded by the Operational Program “Competitiveness, Entrepreneurship and Innovation” (NSRF 2014-2020). Additional assistance was offered by Siemens AG via the project stablishing a Multidisciplinary and Successful Innovation and Entrepreneurship Hub(E-11928). The preparation of your radioligand for the patient study was supported by the CERAD project, financed under Smart Growth Operational Plan 2014020, Priority IV, Measure 4.2. POIR.04.02.004-A001/16. The clinical part of the study obtained monetary assistance in the Poznan University of Healthcare Sciences (grant No. 502-14-22213550-41147). Institutional Critique Board Statement: The animal and patient research have been conducted according to the recommendations of your Declaration of Helsinki. The animal protocols have been approved by the Department of Agriculture and Veterinary Service from the Prefecture of Athens (protocol numbers #1609 for the stability and #1610 for the biodistribution research, both issued on 11 April 2018). The patient study protocol was approved by the Bioethical Committee with the Poznan University of Medical Sciences (decision no. 1153 issued on 16 January 2020). Informed Consent Statement: Sufferers gave th.
